Latest Leukotriene antagonists Stories
Topical market research report “PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023” elaborated by GlobalData has been recently published at MarketPublishers.com.
LifeScienceIndustryResearch.com adds “Singulair (Asthma) – Forecast and Market Analysis to 2023” to its store.
DALLAS, September 19, 2014 /PRNewswire/ -- RnRMarketResearch.com adds asthma drugs market research reports titled "Asthma - Japan Drug Forecast and Market Analysis to 2023",
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rq8jml/investigation) has announced the addition of the "Investigation
A new study shows a rarely-prescribed drug is easier to use and may be just as effective as treatment with inhalers.
A rarely prescribed asthma drug is easier to use and just as effective as conventional treatment with inhalers.
A British study published in the New England Journal of Medicine (NEJM) suggests that pills marketed under brand names such as Singulair and Accolate work just as well as inhalers
NORWICH, England, May 4, 2011 /PRNewswire/ -- A rarely prescribed asthma drug is easier to use and just as effective as conventional treatment with inhalers, according to a new study led by the University of East Anglia (UEA). Publishing tomorrow in the New England Journal of Medicine, the researchers followed 650 patients with chronic asthma for two years.
WARREN, N.J., March 30, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilmÂ® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S.
- A political dynamiter.